The Globe and Mail reports in its Tuesday, July 18, edition that Canaccord Genuity analyst Matt Bottomley has negatively adjusted his share target for Organigram Holdings by $5 to $4 in the wake of the weed company's fiscal third quarter results. The Globe's Darcy Keith writes that Mr. Bottomley continues to rate Organigram "speculative buy." Mr. Bottomley says in a note: "FQ3 saw revenues take a further step back with adj. EBITDA dipping back into negative territory as competition for high THC offerings and lower international shipments weighed notably on results. ... In terms of OGI's operational segments, Canadian adult-use sales sequentially increased 6.5 per cent to $29.2-million; however, after coming down by 24 per cent in the prior quarter, we note that the company's quarterly adult-use contribution is still well below its historical highs. The company experienced notable headwinds in the segment this quarter in relation to Health Canada's decision to ban the production of OGI's high-margin ingestible extracts products, as well as increased competition in products labelled as high THC throughout the country." The Globe reported on April 14 that Stifel rated Organigram "buy." It was then worth $6.